Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTR-CM phase 3 tafamidis trial
NL-OMON41905Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafamidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (3 arms), sponsored by Pfizer. Primary endpoint: Hierarchical combination of all-cause mortality and frequency of cardiovascular-related hospitalizations. Started May 2015; status: active, not recruiting.
02
Drugs
tafamidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON41905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41905.